Police have raided the offices of an organization associated with allies of US health secretary Robert F. Kennedy Jr. that was reportedly planning a vaccine trial in infants which experts described as unethical, according to Ars Technica. The raid is more than a local incident: it goes to the question of who is allowed to supervise clinical research on children.
What is reported
Per Ars Technica, officers searched the premises of a group close to Kennedy that was preparing a vaccine study in infants. The trial was described in the reporting as "unethical." Which agency carried out the raid, the precise identity of the organization, whether any charges have been filed, and whether the study had ethics-board approval or an FDA authorization at all are not established in the material available to us.
Those gaps are not incidental. They decide whether this reads as an attempt to route around an approval process or as a dispute over how rules that apply to everyone should be interpreted.
Why the rules are this strict
Research on children is the most tightly regulated corner of US clinical research. Federal rules (45 CFR 46, Subpart D) permit studies involving minors only in narrow categories: minimal risk, or risk above that threshold when a direct benefit to the child is expected and the risk-benefit balance remains favourable. A child cannot consent; parents may only consent within limits designed to protect the child rather than to facilitate the research. For infants — the weakest group within an already protected group — the bar is highest, and a study without credible ethical review is not "controversial" but simply not permissible.
There is also the oversight chain. A study of an investigational product generally requires a local institutional review board and an FDA investigational new drug authorization. Anyone who bypasses that chain, or tries to, invites not only professional sanction but criminal exposure — which is why a police raid is a notable escalation.
The political context
Kennedy has been health secretary since 2025 and has remade the country's vaccine policy in that role: he replaced the members of the advisory committee that sets vaccine recommendations and positioned himself against federal funding for mRNA vaccines. Whatever one makes of those decisions, the relationship between political leadership and scientific review has shifted.
An infant study planned by people close to the secretary is not a marginal detail in that story. It bears on whether political networks can organise research outside established review, and whether the agencies meant to stop that still act when the pressure is political.
What to watch
Four things will settle the case: whether charges are filed and against whom; whether the organization claims to have ethics-board approval and who supposedly granted it; whether the FDA or another federal agency was involved or bypassed; and whether Congress demands oversight. Until then the sober reading is narrow: there was a raid, there was a planned study, and the rest is open.
